LAVAL, Quebec (BUSINESS WIRE) BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that two abstracts.
- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration (“FDA”) and received scientific advice from the European Medicines Agency (“EMA”) to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 Ended second quarter 2022 with approximately US$384.6 million.
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.